TargetBeta
EZH1
enhancer of zeste 1 polycomb repressive complex 2 subunit · also KIAA0388, KMT6B · Histone lysine methyltransferases
3 programs in company-led studies act on EZH1, from 3 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| tulmimetostat | Novartis | phase 2 | 33 running | EZH2 | the company's pipeline |
| EZH1/2 Inhibitor HH2853rule | Haihe Biopharma | phase 2 | 22 running | EZH2 | NCIt |
| valemetostatrule | Daiichi Sankyo | phase 1 | 11 running | EZH2 | NCIt |
Also acted on by the same programs
Conditions their studies are in
- Prostatic Neoplasms, 2 programs
- Bulbo-Spinal Atrophy, X-Linked, 1 program
- Lymphoma, Follicular, 1 program
- Lymphoma, Large B-Cell, Diffuse, 1 program
- Lymphoma, T-Cell, Peripheral, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 31, 2027EZH1/2 Inhibitor HH2853 · Haihe Biopharma · phase 2 · NCT04390737
- Jan 31, 2028valemetostat · Daiichi Sankyo · phase 1 · NCT07244341
- Nov 9, 2029tulmimetostat · Novartis · phase 2 · NCT07206056
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.